Valeant shares dive despite CEO's return from illness

Shares of Valeant Pharmaceuticals are down sharply in morning trading Monday, amid ongoing turmoil over the embattled drugmaker's delayed financial results and its leader's health.

See Full Article

Even news Sunday that CEO Michael Pearson is returning immediately after nine weeks recovering from pneumonia and unspecified complications failed to buoy Valeant shares.

The shares are trading at less than one-third of their $263.81 high last August. That was right before Valeant's practice of buying rights to old drugs and jacking up the prices came under congressional scrutiny, and a few months before its questionable relationship with a drug distributor raised concerns about the accuracy of its financial reporting.

Valeant shares dropped $6.75, or 8.4 per cent, to $73.90 in midday trading Monday.

Investors appear to be reacting to Valeant's announcement in a statement Sunday that is withdrawing all its financial forecasts.

Nomura equity analyst Shibani Malhotra wrote Monday that while Pearson's return to the helm "is a positive," for the company, she's concerned by Valeant's decision to withdraw its 2016 guidance, which was confirmed just six weeks ago.

Valeant, based in Laval, Quebec, also again delayed announcing its preliminary fourth-quarter and 2015 financial results, which were to be released Monday. The company cited Pearson's return to work as the reason.

"Valeant won't turn around until it restores its credibility, and it doesn't help to bring back the CEO who created the questions about financial reporting on his watch and his handling of questions about Philidor," Erik Gordon, a professor and pharmaceuticals analyst at University of Michigan's Ross School of Business, wrote in an email.

Pearson's convalescence, and the limited information the company released about his condition, aren't the only concerns dragging down Valeant shares.

Last Tuesday, Valeant said it would delay filing its 2015 annual report with regulators while it sorts out its former relationship with the mail-order pharmacy Philidor. Valeant said it expected to lower reported 2014 earnings by about 10 cents per share and raise 2015 earnings by about 9 cents. That's because about $58 million in sales to Philidor were improperly recognized too early -- when they were delivered to Philidor, rather than when patients received the products.

Moody's Investor's Service on Tuesday revised Valeant's outlook to negative from stable, but noted that the amount of revenue misstated "appears relatively minor."

Valeant cut ties with Philidor last fall amid allegations that Philidor created a network of "phantom pharmacies" to steer pharmacy benefit managers toward Valeant's more-expensive drugs instead of cheaper alternatives.

Responding to public criticism over its huge price increases for some products, Valeant's interim CEO, Howard Schiller, on Feb. 2 told a House committee investigating high drug prices that he froze all of Valeant's price increases when he took over in January. He said Valeant would aim for more modest price increases in the future.

Schiller is to transition out of his temporary CEO duties but remain a member of Valeant's board. The board also decided to split the roles of chairman and CEO, both of which had been held by Pearson, and appoint Robert A. Ingram as chairman of the board. Ingram has been on Valeant's board since 2010 and previously served as chairman for a few months at the start of 2011.

The board said in the statement that planning for Pearson's successor and expanding Valeant's senior management "are high priorities."

Jeffrey Loo, equity analyst at S&P Global Market Intelligence, wrote Monday that "the return of Mr. Pearson and (Valeant's) efforts to build out its management team for succession planning should provide some stability" and that he maintains a "Buy" recommendation on the stock.


Latest Economic News

  • TSX ends down along with U.S. markets, Canadian dollar makes slight gains

    Economic CBC News
    Canada's main stock index joined U.S. markets in the red Monday as a Federal Reserve meeting looms and a share price hit at Facebook over improper data use weighed on the tech sector. The S&P/TSX composite index closed down 121.94 points to 15,589.39, led by declines in energy and base metals as both oil and copper prices slipped. Source
  • Analyst warns B.C. gas prices could soon hit a record high

    Economic CTV News
    VANCOUVER -- Drivers in British Columbia should brace for record high gasoline prices this summer and the financial pain has the potential to spread across the country, says a petroleum industry analyst. Dan McTeague of the online tech company GasBuddy predicts that beginning in April and continuing to September, gasoline prices across much of B.C. Source
  • Facebook shares fall as EU, U.S. urge probes of data practices

    Economic CBC News
    Facebook Inc. faced growing pressure on Monday after European and U.S. lawmakers called for investigations into reports that a consultancy that worked on President Donald Trump's campaign gained access to data on 50 million Facebook users. Source
  • Nordstrom Rack to open first Canadian store in Vaughan, Ont., Toronto to follow

    Economic CTV News
    TORONTO -- American department store Nordstrom is opening the first Canadian location of its discount Rack chain on Thursday. The 35,000-square-foot store will be situated north of Toronto at Vaughan Mills mall. It is promising savings of up to 70 per cent on products from 38 of the 50 brands already sold in its Canadian department stores. Source
  • Greenpeace says brands refusing to reveal palm oil sources

    Economic CTV News
    JAKARTA, Indonesia -- Greenpeace says several major household brands including Hershey and Johnson & Johnson have failed to disclose where they get their palm oil from despite vows to stop buying from companies that cut down tropical forests to grow the widely used commodity. Source
  • 'Took fake news to the next level': Facebook data whistleblower on U.S. election

    Economic CTV News
    NEW YORK -- A Trump-affiliated firm under scrutiny for inappropriately obtaining data on tens of millions of Facebook users created profiling algorithms that "took fake news to the next level," a former employee said. Chris Wylie said the firm, Cambridge Analytica, secured personal data in order to learn about individuals and then used it to create an information cocoon to change their perceptions. Source
  • How Facebook likes could profile voters for manipulation

    Economic CTV News
    NEW YORK -- Facebook likes can tell a lot about a person. Maybe even enough to fuel a voter-manipulation effort like the one a Trump-affiliated data-mining firm stands accused of -- and which Facebook may have enabled. Source
  • Claire's files for bankruptcy, Canadian stores spared

    Economic CTV News
    NEW YORK -- Claire's, the mall chain that has pierced the ears of millions of teens, has filed for Chapter 11 bankruptcy protection in the U.S. but its Canadian and European stores are not involved. Source
  • Lightning fast wireless is on the way: here's how 5G will change life in Canada

    Economic CBC News
    The federal, Ontario and Quebec governments say they will spend $200 million to help fund research into 5G wireless technology, the next-generation networks with download speeds 100 times faster than current ones can handle. The so-called "5G corridor," known as ENCQOR, will see tech companies such as Ericsson, Ciena Canada, Thales Canada, IBM and CGI kick in another $200 million to develop facilities to get the project up and running. Source
  • Via Rail to launch process to buy new trains with federal funding announcement

    Economic CTV News
    ETOBICOKE, Ont. -- Via Rail is preparing to launch a process to replace aging trains on its main Canadian corridor after federal Transport Minister Marc Garneau announced funding Monday by the government. The national passenger service says it will launch a request for qualifications, followed by a request for proposals. Source